



---

## NEWS RELEASE

### ONTARIO'S RESPONSE TO H1N1 PANDEMIC

For immediate release  
June 2, 2010

Jeremy Carver, Chief Executive Officer and Chief Scientific Officer for the Peterborough , ON, based International Consortium on Anti-Virals (ICAV) - Consortium International sur les Thérapies Antivirales (CITAV) – agreed today with the CMOH, Dr. Arlene King, that Ontario did well in its reaction to the recent H1N1 pandemic but could do better in the future.

ICAV, a not-for-profit organisation, is currently researching a promising new treatment to tackle future pandemic outbreaks of H1N1. ICAV was founded in the wake of the SARS epidemic to discover and develop anti-viral therapies for neglected and emerging diseases and to ensure their accessibility to all those in need.

Responding to the release of a new report from Dr. Arlene King, Ontario's Chief Medical Officer of Health (CMOH), Dr Carver commented: “Our analysis agrees with the CMOH's conclusion - the high level of vaccination avoided a third wave in Ontario.

Ontario did well but had the virus been more aggressive we would have been much worse off - we need better treatments for those patients hospitalized so we can reduce the number of patients that need to be treated in the ICU and the deaths that followed. Better treatment would also significantly reduce costs to the system of another pandemic.”

ICAV has been working with the Ontario Agency for Health Protection and Promotion (OAHPP) to develop a truly human monoclonal antibody platform that could supply those treatments in a future pandemic.

ICAV is in discussion with funding agencies to obtain the investments that would allow the platform to provide treatments in time to treat the second wave in a future pandemic.

About ICAV:

ICAV, headquartered at Trent University in Peterborough, is an institutional innovation - a not-for-profit drug development and discovery company - dedicated to the discovery and development of anti-viral therapies for neglected and emerging diseases. Through the international collaboration of scientists, government and industry, ICAV's goal is to deliver at least one novel drug to market every five years that is affordable, effective, and globally accessible to all patients in need. ICAV:

- fills the gap between academic research and clinical development
- accelerates development of drugs for neglected and emerging viral diseases
- ensures global access to novel therapies at affordable prices

For further information or comment, please contact Simon Cooper, ICAV Director of Communications.

Tel: 705-748 1011 x6277

Cell: 450-240 5283

Email: [simon.cooper@icav-citav.ca](mailto:simon.cooper@icav-citav.ca)

Visit us at:

[www.icav-citav.ca](http://www.icav-citav.ca)

Twitter:

<http://twitter.com/ICAVCITAV>